Biopharma
Atlas Venture Raises $400M Opportunity Fund to Bolster Biotech Portfolio
Atlas Venture; $400M growth fund; biotech startups; Opportunity Fund III; portfolio support; venture capital; late-stage funding; biopharma investment
Endpoints News to Announce 2025 ‘Endpoints 11’ Biotechs to Watch Live in Boston
Endpoints 11; biotech startups; biopharma; Boston; live event; industry trends; biotech innovation
Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal
Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments
Johnson & Johnson Commits $2B to Fujifilm North Carolina Site in Latest US Manufacturing Push
Johnson & Johnson; Fujifilm; manufacturing; North Carolina; $2 billion investment; biopharma; job creation; US manufacturing
Sarepta Extends $700M Debt to 2030, Adds Private Placement Amid Elevidys Uncertainty
Sarepta Therapeutics; debt maturity extension; convertible notes; private placement; Elevidys; financial strategy; biopharma
Endpoints 11: Biopharma’s most promising startups revealed live in Boston this September
Endpoints 11; biotech startups; biopharma; Boston event; State Room; awards gala; early bird rate; industry insiders; 2025 most promising biotechs; real-time reveal
Trump Announces Massive Pharma Tariffs Up to 250%, Signals Enforcement Within Days
Trump; pharma tariffs; tariff increase; biopharma; Canada; Section 301; international trade; fentanyl crisis
How Science Drives Better Business Decisions in Biopharma (2025 Update)
biopharma; decision science; AI; digital twins; R&D; portfolio strategy; data-driven decisions; innovation; business strategy
Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market
Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal
Biotech Layoff Wave Hits Karyopharm, Century, and Pacira in 2025
biotech layoffs; Karyopharm Therapeutics; Century Therapeutics; Pacira; 2025 workforce reductions; biopharma restructuring